Drug Database
PR

pregabalin (pregabalin, YuHan / YHD 1119 / YHD1119)

✓ Approved

YuHan · CACNA2D1 · Small Molecule

What is pregabalin?

pregabalin is a small molecule developed by YuHan. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namespregabalin, YuHan, YHD 1119, YHD1119
CompanyYuHan
Drug ClassSmall Molecule
Molecular TargetCACNA2D1
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, YuHan

Mechanism of Action

Molecular Targets

pregabalin acts on 1 molecular target:

CACNA2D1calcium voltage-gated channel auxiliary subunit alpha2delta 1 (LINC01112, CACNA2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pregabalin is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersDiabetic neuropathy✓ Approved
Nervous system disordersPost herpetic neuralgia✓ Approved

Related Research Articles

PubMedJournal of mass spectrometry and advances in the clinical lab2026-11-11

A Multiplex LC-MS/MS Approach for Quantifying Antiepileptic Drugs for Therapeutic Drug Monitoring: Validation of 15 Representative Tests.

Tang Xiaoying X, Wei Ruhan R, Chegwidden Emily E, Giles Richard R et al.

Therapeutic drug monitoring of antiepileptic drugs is critical for optimizing clinical outcomes, minimizing toxicity, assessing drug compliance, and managing overdoses and drug interactions. We developed and validated an LC-MS/MS method for the quantification of 15 antiepileptic drugs (ethosuximide, primidone, pentobarbital, carbamazepine-10,11 epoxide, pregabalin, gabapentin, zonisamide, lacosamide, rufinamide, felbamate, lamotrigine, topiramate, 10,11-dihydro-10-hydroxycarbamazepine, perampanel, and brivaracetam). Antiepileptic drugs were extracted from plasma and serum using methanol-based protein precipitation, followed by dilution. A commercial ClinCal® 3-point calibrator was used for all analytes except pentobarbital, which used a 6-point in-house calibrator. Chromatographic separation was achieved using a reverse-phase C18 column with a 7.31 min elution gradient of water and methanol, both containing 2 mM of ammonium acetate. All analytes required a 5 µL injection volume, except ethosuximide and pentobarbital, which required 20 µL and 10 µL, respectively, for optimal performance. The method demonstrated excellent linearity for all 15 antiepileptic drugs within their respective concentration ranges, with acceptable selectivity, accuracy (80.0-118.3%), and intraday and interassay precision (CV < 7.4%). Stability studies showed that antiepileptic drugs were stable in serum and plasma for up to 24 h at room temperature, 7 days at 4 °C, and 30 days at -20 °C, and after extraction for 7 days at 4 °C. This LC-MS/MS method supports routine quantification of 15 antiepileptic drugs in a clinical laboratory using a common sample preparation and chromatography workflow across all measurements. It was operationalized into three instrument methods to accommodate the different injection volume and calibrator requirements.

PMID 43011968
Read full article →
PubMedCureus2026-11-09

Severe Primary Varicella-Zoster Virus Meningitis With Dual Cranial Neuropathy (Cranial Nerve VII and Cranial Nerve XII) in a 67-Year-Old Man With Post-traumatic Asplenia: A Case Report.

Ostatishvili Khatia K, Chaprava Tamari T, Babutsidze Sopio S, Nadimashvili Paata P et al.

Primary varicella-zoster virus (VZV) infection in adults can cause severe systemic and neuroinvasive complications, particularly in older patients and those with impaired splenic function. A 67‑year‑old man with post-traumatic asplenia and hypertension presented on day five of varicella with acute viral meningitis, right peripheral facial nerve palsy (cranial nerve (CN) VII), and right hypoglossal nerve palsy (CN XII). Cerebrospinal fluid (CSF) analysis, including multiplex polymerase chain reaction (PCR) testing, confirmed VZV infection with lymphocytic pleocytosis and elevated protein levels. Contrast-enhanced magnetic resonance imaging of the brain revealed localized leptomeningeal enhancement without brainstem or parenchymal involvement. Following diagnosis, an appropriate course of intravenous and oral antiviral therapy was administered, resulting in a marked clinical and laboratory response. Oral pregabalin was initiated and titrated for persistent subacute neuropathic pain. Meningitis and systemic infection resolved, and the patient was discharged in stable condition with outpatient follow‑up for CN recovery and neuralgia management. This case highlights the risk of severe neuroinvasive VZV in older asplenic patients and supports early CSF PCR testing and prompt initiation of extended antiviral therapy in high‑risk individuals.

PMID 43001048
Read full article →
PubMedCureus2026-11-08

Hybrid Osteosynthesis for Septic Humeral Shaft Nonunion in a Patient with Obesity: A Case Report.

Chiquini-Ramírez Paolo P, Villamues-Moreno Nancy Lorena NL, Ponce-de-Léon-Dominguez Jorge J, Moreno-Degante Leonardo L et al.

Septic humeral shaft nonunion represents a complex reconstructive challenge in orthopedic surgery, particularly in patients with obesity, in whom increased lever arms and greater mechanical loading of the upper extremity substantially compromise fixation stability. Recurrent failure of isolated fixation constructs, including intramedullary nails or compression plates, necessitates hybrid strategies that combine enhanced biomechanical stability with effective eradication of microbial infection. This article presents the case of a middle-aged man with obesity and a history of a left humeral shaft fracture initially treated with intramedullary nailing in December 2020 who developed persistent nonunion. Following revision surgery with dynamic compression plating, fixation failure occurred secondary to implant fatigue. A second revision procedure was performed through a posterior approach, including nerve neurolysis, extensive debridement, and hybrid fixation using a 240 x 8 mm Targon™ H intramedullary nail (B. Braun, Melsungen, Germany) combined with a narrow 4.5-mm dynamic compression plate (DCP; DePuy Synthes, Warsaw, IN, USA). Cancellous bone chip grafting was also performed. Intraoperative cultures yielded Staphylococcus epidermidis, establishing the diagnosis of septic nonunion, and targeted oral clindamycin therapy was initiated. Despite transient postoperative radial neuropraxia, which resolved with pregabalin treatment and structured physical rehabilitation, the patient achieved complete osseous union, eradication of infection, and an Upper Extremity Functional Scale (UEFS) score of 69/80, corresponding to 86% of maximal functional capacity. In conclusion, hybrid fixation combining an intramedullary nail with a narrow 4.5-mm DCP, together with pathogen-directed antimicrobial therapy, provides excellent axial and rotational stability and represents an effective salvage strategy for septic humeral shaft nonunion in patients with increased biomechanical demands.

PMID 42999717
Read full article →
PubMedJournal of the American Veterinary Medical Association2026-11-06

Pregabalin and gabapentin in fractious cats: an exploratory comparison of handling-related outcomes and adverse effect profiles.

Measson Cyrille C, Fournier Floriane F, Sarcey Guillaume G, Béata Claude C

To compare pregabalin and gabapentin on manageability, ease of placing into a carrier, ease of transport, and adverse effects in cats exhibiting fractious behavior. An exploratory double-blind, randomized crossover study enrolled 32 cats with a history of fractious behavior. Each cat received pregabalin (5 mg/kg; Bonqat) or gabapentin (compounded, 20 mg/kg), administered 2 hours before examination, with treatments allocated in random order 15 days apart. Outcomes included manageability (veterinarian-recorded), ease of placing the cat into the carrier (owner-reported), transport (owner-reported), and adverse effects (owner-reported and veterinarian-recorded). Median scores (with IQRs) overlapped between pregabalin and gabapentin for manageability, ease of placing the cat into the carrier, and ease of transport. Owner-reported adverse effects did not differ between treatments, and drowsiness and muscle relaxation were the most frequently owner-reported effects, while veterinarian-recorded adverse effects were more frequent with gabapentin. Marked interindividual variability was observed: some cats responded substantially better to one drug than to the other. In this exploratory study, pregabalin and gabapentin provided overlapping outcomes for handling-related outcomes in fractious cats but differed in their adverse effect profiles, with gabapentin associated with a greater frequency of clinician-observed effects. The cat-dependent variation in response warrants further investigation. Both gabapentinoids produced comparable handling-related outcomes in fractious cats. When adverse effect burden is a concern, pregabalin may offer a marginally favorable safety profile. Individual variation in drug response suggests that if one agent proves ineffective, the other may be trialed.

PMID 42994090
Read full article →
PubMedMedicine2026-11-06

Magnetic resonance neurography-supported L3-L4 radiculitis presenting as refractory peripatellar neuropathic pain in a patient with diabetes: A case report.

Huang Xue X, Yang Dan D, Wang Jie J, Zheng Bixin B

Peripatellar pain is usually attributed to local knee disorders. However, proximal neural lesions can also cause pain around the knee. Third and fourth lumbar (L3-L4) radiculitis presenting mainly as peripatellar neuropathic pain is uncommon and may be missed when typical radicular symptoms are absent. A 75-year-old man with a more than 20-year history of type 2 diabetes presented with severe left peripatellar pain for 10 days. The pain was burning and stabbing and was accompanied by numbness and marked touch-evoked allodynia. The visual analog scale score was 8-9/10, and the Douleur Neuropathique 4 score was 9/10. He had no low back pain, typical radicular pain, motor weakness, or reflex abnormalities. Knee magnetic resonance imaging showed degenerative changes that did not explain the neuropathic pain phenotype. Lumbar magnetic resonance imaging showed no definite compression of the L3 or L4 nerve roots. Electrodiagnostic testing did not provide level-specific localization. Magnetic resonance neurography showed asymmetric hyperintensity involving the left L3 and L4 proximal neural structures, supporting the diagnosis of L3-L4 radiculitis. Neuropathic pain medications and knee-targeted procedures provided inadequate or only transient relief. The patient was subsequently treated with pregabalin, duloxetine, short-term opioid analgesia, and optimization of glycemic control. The pain and allodynia gradually improved within 2 weeks, and analgesic medications were discontinued. At 3 months, the visual analog scale score was 0-3/10 and the Douleur Neuropathique 4 score was 1/10. Touch-evoked allodynia had resolved. L3-L4 radiculitis may present as refractory peripatellar neuropathic pain without low back pain or typical radicular symptoms. When severe neuropathic pain around the knee cannot be explained by local pathology, a proximal neural lesion should be considered. Magnetic resonance neurography may help identify radiculitis that is not evident on conventional lumbar imaging.

PMID 42994842
Read full article →
PubMedRevista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)2026-11-06

Drugs Associated with Dementia-Related Adverse Event Reports: A Real World Pharmacovigilance Study.

Huang Mengjie M, Ren Honghao H, Ren Xiaodong X, Wen Pengfei P et al.

Numerous pharmacological agents have been implicated in elevating the risk of dementia onset. The present study employs a systematic methodology to examine drugs associated with dementia-related adverse event reports. The present study extracted case of drugs associated with dementia-related adverse event reports from the FDA Adverse Event Reporting System (FAERS) covering the period from the first quarter of 2004 to the first quarter of 2025. The Reporting Odds Ratio (ROR) was employed as the principal metric for disproportionality analysis. Methodological robustness was validated through the application of the Proportional Reporting Ratio (PRR), the Bayesian Confidence Propagation Neural Network (BCPNN), and the Multi-item Gamma Poisson Shrinker (MGPS). Variable selection was facilitated using least absolute shrinkage and selection operator (LASSO) regression. Temporal relationships were examined via Time-to-Onset analysis. Clinical outcomes among patients with dementia-related adverse event reports were evaluated, including rates of mortality and disability. Furthermore, the clinical indications for the implicated pharmaceuticals were systematically investigated. A total of 13 pharmaceutical agents were ultimately identified as exhibiting a potential association with dementia onset: Apixaban, Insulin glargine, Tafamidis, Insulin lispro, Sacubitril valsartan, Quetiapine, Zoledronic acid, Alendronic acid, Enzalutamide, Pregabalin, Rofecoxib, Dapagliflozin, and Valproic acid. The median time to dementia development following drug initiation was 73 days (interquartile range: 529 days), indicating that 75% of reported cases occurred within approximately 1.45 years post-exposure. Furthermore, the top five agents associated with the highest mortality rates in dementia-related adverse event reports associated with drug exposure were identified as Rofecoxib, Zoledronic acid, Tafamidis, Alendronic acid and Enzalutamide, while the top five agents linked to the highest disability rates included Valproic acid, Alendronic acid, Insulin glargine, Rofecoxib and Zoledronic acid. Finally, the primary clinical indications for these 13 drugs were analyzed. Clinicians should exercise heightened vigilance regarding the potential onset of dementia when utilizing these medications in patient care. These findings contribute to early signal detection for pharmacologically associated dementia and may guide clinical medication management, yet they remain pharmacovigilance signals that require prospective confirmation.

PMID 42993875
Read full article →

+5401 more articles available with a free account

Sign up free to view all articles →

Ask about pregabalin